A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma

NCT00533702 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

106

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Malignant Melanoma

Interventions

BIOLOGICAL: IMC-1121B (ramucirumab)
DRUG: Dacarbazine

Sponsor

Eli Lilly and Company